These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

283 related articles for article (PubMed ID: 29382672)

  • 1. Time in therapeutic range and stability over time for warfarin users in clinical practice: a retrospective cohort study using linked routinely collected health data in Alberta, Canada.
    McAlister FA; Wiebe N; Hemmelgarn BR
    BMJ Open; 2018 Jan; 8(1):e016980. PubMed ID: 29382672
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Suboptimal Anticoagulant Management in Japanese Patients with Nonvalvular Atrial Fibrillation Receiving Warfarin for Stroke Prevention.
    Hirano T; Kaneko H; Mishina S; Wang F; Morita S
    J Stroke Cerebrovasc Dis; 2017 Oct; 26(10):2102-2110. PubMed ID: 28532651
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Warfarin Management and Outcomes in Patients with Nonvalvular Atrial Fibrillation Within an Integrated Health Care System.
    An J; Niu F; Zheng C; Rashid N; Mendes RA; Dills D; Vo L; Singh P; Bruno A; Lang DT; Le PT; Jazdzewski KP; Aranda G
    J Manag Care Spec Pharm; 2017 Jun; 23(6):700-712. PubMed ID: 28530526
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Quality of warfarin control in atrial fibrillation patients in South East Queensland, Australia.
    Bernaitis N; Badrick T; Davey AK; Anoopkumar-Dukie S
    Intern Med J; 2016 Aug; 46(8):925-31. PubMed ID: 27040159
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Quality of anticoagulant control and patient experience associated with long-term warfarin in Canadian patients with non-valvular atrial fibrillation: A multicentre, prospective study.
    Selby R; Kaus L; Sealey F; Koo M; Parpia S; Chan B; Seung SJ; Bradley C; Strauss R; Mittmann N
    PLoS One; 2023; 18(4):e0284425. PubMed ID: 37071625
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Time in Therapeutic Range and Outcomes After Warfarin Initiation in Newly Diagnosed Atrial Fibrillation Patients With Renal Dysfunction.
    Szummer K; Gasparini A; Eliasson S; Ärnlöv J; Qureshi AR; Bárány P; Evans M; Friberg L; Carrero JJ
    J Am Heart Assoc; 2017 Mar; 6(3):. PubMed ID: 28249846
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Evaluation of the impact of warfarin time in therapeutic range on outcomes of patients with atrial fibrillation in Turkey: perspectives from the observational, prospective WATER Registry.
    Turk UO; Tuncer E; Alioglu E; Yuksel K; Pekel N; Ozpelit E; Vuran O; Tengiz I
    Cardiol J; 2015; 22(5):567-75. PubMed ID: 26100825
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Improving quality measurement for anticoagulation: adding international normalized ratio variability to percent time in therapeutic range.
    Razouki Z; Ozonoff A; Zhao S; Jasuja GK; Rose AJ
    Circ Cardiovasc Qual Outcomes; 2014 Sep; 7(5):664-9. PubMed ID: 25185245
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effect of suboptimal anticoagulation treatment with antiplatelet therapy and warfarin on clinical outcomes in patients with nonvalvular atrial fibrillation: A population-wide cohort study.
    Chan EW; Lau WC; Siu CW; Lip GY; Leung WK; Anand S; Man KK; Wong IC
    Heart Rhythm; 2016 Aug; 13(8):1581-8. PubMed ID: 27033342
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Quality of warfarin management in primary care: Determining the stability of international normalized ratios using a nationally representative prospective cohort.
    Liu S; Singer A; McAlister FA; Peeler W; Heran BS; Drummond N; Manca DP; Allan GM; Korownyk C; Kolber MR; Greiver M; Garrison SR
    Can Fam Physician; 2019 Jun; 65(6):416-425. PubMed ID: 31189630
    [TBL] [Abstract][Full Text] [Related]  

  • 11. D-Dimer versus International Normalized Ratio of Prothrombin Time in Ischemic Stroke Patients Treated with Sufficient Warfarin.
    Yamamoto R; Nakae Y; Tanaka F; Johkura K
    J Stroke Cerebrovasc Dis; 2016 Jul; 25(7):1781-1785. PubMed ID: 27103270
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Causes of Ischemic Stroke in Patients with Non-Valvular Atrial Fibrillation.
    Nakamura A; Kuroda J; Ago T; Hata J; Matsuo R; Arakawa S; Kuwashiro T; Yasaka M; Okada Y; Kitazono T; Kamouchi M;
    Cerebrovasc Dis; 2016; 42(3-4):196-204. PubMed ID: 27111222
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Association Between Warfarin Control Metrics and Atrial Fibrillation Outcomes in the Outcomes Registry for Better Informed Treatment of Atrial Fibrillation.
    Pokorney SD; Holmes DN; Thomas L; Fonarow GC; Kowey PR; Reiffel JA; Singer DE; Freeman JV; Gersh BJ; Mahaffey KW; Hylek EM; Naccarelli GV; Ezekowitz MD; Piccini JP; Peterson ED;
    JAMA Cardiol; 2019 Aug; 4(8):756-764. PubMed ID: 31268487
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Genetic and Non-Genetic Factors Affecting the Quality of Anticoagulation Control and Vascular Events in Atrial Fibrillation.
    Park YK; Lee MJ; Kim JH; Lee JS; Park RW; Kim GM; Chung CS; Lee KH; Kim JS; Lee SY; Bang OY
    J Stroke Cerebrovasc Dis; 2017 Jun; 26(6):1383-1390. PubMed ID: 28412319
    [TBL] [Abstract][Full Text] [Related]  

  • 15. How well does the target INR level maintain in warfarin-treated patients with non-valvular atrial fibrillation?
    Kim JH; Song YB; Shin DH; Kim JS; Choi JO; On YK; Kim JS
    Yonsei Med J; 2009 Feb; 50(1):83-8. PubMed ID: 19259353
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Risks of stroke and mortality associated with suboptimal anticoagulation in atrial fibrillation patients.
    Gallagher AM; Setakis E; Plumb JM; Clemens A; van Staa TP
    Thromb Haemost; 2011 Nov; 106(5):968-77. PubMed ID: 21901239
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Patients' time in therapeutic range on warfarin among US patients with atrial fibrillation: Results from ORBIT-AF registry.
    Pokorney SD; Simon DN; Thomas L; Fonarow GC; Kowey PR; Chang P; Singer DE; Ansell J; Blanco RG; Gersh B; Mahaffey KW; Hylek EM; Go AS; Piccini JP; Peterson ED;
    Am Heart J; 2015 Jul; 170(1):141-8, 148.e1. PubMed ID: 26093875
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Anticoagulation control and cost of monitoring of older patients on chronic warfarin therapy in three settings in North East England.
    Abohelaika S; Kamali F; Avery P; Robinson B; Kesteven P; Wynne H
    Age Ageing; 2014 Sep; 43(5):708-11. PubMed ID: 24947831
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Impact of global geographic region on time in therapeutic range on warfarin anticoagulant therapy: data from the ROCKET AF clinical trial.
    Singer DE; Hellkamp AS; Piccini JP; Mahaffey KW; Lokhnygina Y; Pan G; Halperin JL; Becker RC; Breithardt G; Hankey GJ; Hacke W; Nessel CC; Patel MR; Califf RM; Fox KA;
    J Am Heart Assoc; 2013 Feb; 2(1):e000067. PubMed ID: 23525418
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Variability of INR and its relationship with mortality, stroke, bleeding and hospitalisations in patients with atrial fibrillation.
    Lind M; Fahlén M; Kosiborod M; Eliasson B; Odén A
    Thromb Res; 2012 Jan; 129(1):32-5. PubMed ID: 21851969
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.